Low-Value Intravenous Infusion / 低价值静脉输液

Definition

Low-value intravenous infusion is intravenous treatment used without a clear patient-specific indication when oral care, observation, or evidence-based prevention can provide similar benefit with less procedural risk, infection exposure, and resource use.

Current Synthesis

VOL.194 develops the concept through two common expectations: that an uncomplicated cold or influenza-like illness improves because treatment enters a vein, and that seasonal infusion can “clear blood vessels” or prevent cardiovascular and cerebrovascular disease. The episode argues that route intensity is not the same as treatment value. Saline and symptom-relief medicines may add little over oral fluids, rest, and appropriate oral medication in an uncomplicated illness, while venous puncture, direct drug exposure, allergy, travel, waiting, and contact with infectious patients create additional burdens.

The boundary is indication, not an absolute rejection of intravenous care. A person who cannot maintain hydration, has physiological instability, a serious infection, organ dysfunction, or another qualified indication may need intravenous treatment. Likewise, cardiovascular secondary prevention should follow an established diagnosis and individualized plan rather than periodic infusion as ritual reassurance.

Key Claims

• Intravenous delivery is not inherently more effective than appropriate oral treatment for an uncomplicated viral illness.
• Puncture, direct vascular drug exposure, allergy, and healthcare-setting infection exposure create real burdens even when the infusion seems routine.
• Seasonal infusion to “clear blood vessels” or prevent vascular events lacks support in the episode’s account and can displace evidence-based long-term prevention.
• The relevant question is whether hydration, route, and medicine have a patient-specific indication, not whether infusion feels stronger or faster.
• Avoiding low-value infusion protects both the patient and scarce clinical capacity while preserving intravenous care for genuine need.

Evidence

• Viral-illness route and benefit: VOL.194 contrasts routine infusion for uncomplicated cold or influenza-like illness with rest, oral hydration, symptom relief, and deterioration-aware reassessment.
• Procedure and exposure burden: VOL.194 identifies venous puncture, allergy risk, inconvenience, crowding, and cross-infection as costs that an apparently simple infusion can add.
• Prevention misconception: VOL.194 rejects autumn or winter “blood-vessel clearing” infusion and instead points toward diagnosis-based secondary prevention under medical supervision.

Counterevidence & Qualifications

The source is one clinician’s public-education account and does not supply trials, a formal appropriateness guideline, or a complete list of indications and contraindications. Intravenous fluids and medicines can be essential for dehydration, shock, severe infection, inability to use the gastrointestinal route, and many other conditions. The episode’s named medicines, home-care suggestions, and prevention examples are not individualized treatment advice; route and treatment decisions require current qualified assessment.

What Changed

• Created a route-versus-indication framework for distinguishing reassurance-driven infusion from clinically necessary intravenous treatment.
• Added patient risk, cross-infection exposure, and scarce-capacity use to the assessment of treatment value.

Related Concepts

• Influenza Home-Care and Medication Triage / 流感居家照护与用药分诊 - home-care and escalation framework for uncomplicated versus worsening respiratory illness.
• Medication Self-Combination Risk / 药物自行叠加风险 - adjacent safety problem involving unnecessary or duplicative drug exposure.
• Antimicrobial Resistance - population-level harm when reassurance-driven treatment includes unnecessary antibiotics.
• Emergency-Department Risk Exclusion / 急诊危重风险排除 - acute-risk pathway that should not become a convenience route for low-value treatment.
• Medical Risk Management - broader comparison of plausible benefit, downside, uncertainty, and professional responsibility.